As landscapes change,
so does your thinking
The unmet medical needs
Achieving greater depths of response and reducing the risk of progression and metastasis are paramount in the treatment of patients with NSCLC.1
Next-generation TKIs with a range of anti-tumor activity beyond the first-line treatment setting are needed to improve overall survival and quality of life.1
NSCLC: non-small-cell lung cancer; TKI: tyrosine kinase inhibitor.
1. Planchard D, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–237.